详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiotherapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China. [2]Institute of Biomedical Engineering, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, China.

出处：

DOI：

ISSN：

关键词： tumour tumour-associated endothelial cells characteristics metastasis anti-angiogenic therapy

摘要：

Tumour progression and metastasis remain the leading causes of cancer-related death worldwide. Tumour angiogenesis is essential for tumour progression. The vasculature surrounding tumours is not only a transport channel for nutrients, oxygen, and metabolites, but also a pathway for metastasis. There is a close interaction between tumour cells and endothelial cells in the tumour microenvironment. Recent studies have shown that tumour-associated endothelial cells have different characteristics from normal vascular endothelial cells, play an important role in tumour progression and metastasis, and are expected to be a key target for cancer therapy. This article reviews the tissue and cellular origin of tumour-associated endothelial cells and analyses the characteristics of tumour-associated endothelial cells. Finally, it summarises the role of tumour-associated endothelial cells in tumour progression and metastasis and the prospects for their use in clinical anti-angiogenic therapy.Copyright © 2023 Yao and Zeng.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区生理学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区生理学

第一作者：

第一作者机构： [1]Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiotherapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Tumor angiogenesis and anti-angiogenic therapy [2]Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review). [3]Enhanced tumor radiosensitivity by a survivin dominant-negative mutant [4]Enhanced tumor radiosensitivity by a survivin dominant-negative mutant [5]Evaluation of Antitumor Immunity by a Combination Treatment of Radiation, Anti-PD1, and Anti-Angiogenic Therapy in Esophageal Squamous Cell Carcinoma [6]放射治疗联合抗肿瘤血管治疗研究进展 [7]Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis [8]PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study [9]Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy [10]Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy